Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.

Drug Category : Array

Conference Category : Array

Lead Author : Burris H, Flinn I, et al.

Published Date : 03/06/2016

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASCO%20Integrated%20Analysis%20Poster%20FINAL.pdf

Download Text : Download

Popup Confirmation? :

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

stick-header-meta : default

astra-migrate-meta-layouts : set